The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Ildiko Lingvay is Professor in the Division of Endocrinology and the
Department of Population and Data Sciences at the University of Texas
(UT) Southwestern Medical Center in Dallas, TX, USA. She also serves
as Medical Director of the Office of Clinical Trials Management
overseeing the institutional review and approval of all clinical
studies and clinical trials at UT Southwestern. She sees patients at
the university clinics and hospital, as well as at the Parkland Health
System.
Dr Lingvay leads a clinical research
programme in the field of obesity, diabetes and associated metabolic
complications with the ultimate goal of improving the lives of all
patients who suffer from the many health consequences of these
conditions. Her research interests span the spectrum from
pathophysiology of the disease to comparative effectiveness of
therapeutic approaches. She has participated in many clinical trials
in the field and has a special interest in cardiovascular trials in
diabetes and obesity. She has published over 100 manuscripts in major
medical journals and has contributed to several diabetes textbooks.
She is an active member of the American Diabetes Association, where
she served on the Scientific Sessions Organizing Committee and
currently is on the grant review committee and a board member of the
WIN ADA and Focus on Fellows initiatives.